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Abstract 
Purpose: Schemes with high doses per fraction and small number of fractions are commonly used in high-dose-rate 
brachytherapy (HDR-BT) for prostate cancer. Our aim was to analyze the differences between published clinical results 
and the predictions of radiobiological models for absorbed dose required in a single fraction monotherapy HDR-BT. 
Material and methods: Published HDR-BT clinical results for low- and intermediate-risk patients with prostate 
cancer were revised. For 13 clinical studies with 16 fractionation schedules between 1 and 9 fractions, a dose-response 
relation in terms of the biochemical control probability (BC) was established using Monte Carlo-based statistical meth-
ods. 
Results: We obtained a value of α/β = 22.8 Gy (15.1-60.2 Gy) (95% CI) much larger than the values in the range 
1.5-3.0 Gy that are usually considered to compare the results of different fractionation schemes in prostate cancer 
radiotherapy using doses per fraction below 6 Gy. The doses in a single fraction producing BC = 90% and 95% were 
22.3 Gy (21.5-24.2 Gy) and 24.3 Gy (23.0-27.9 Gy), respectively. 
Conclusions: The α/β obtained in our analysis of 22.8 Gy for a range of dose per fraction between 6 and 20.5 Gy 
was much greater than the one currently estimated for prostate cancer using low doses per fraction. This high value of 
α/β explains reasonably well the data available in the region of high doses per fraction considered. 
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Purpose 
Apart from prostatectomy, radiotherapy is the most 
used therapeutic option for localized prostate cancer, 
with external beam radiotherapy (EBRT), brachytherapy 
(BT), or both techniques applied. Since mid-1990s, high-
dose-rate-brachytherapy (HDR-BT) started to be used as 
monotherapy [1,2,3] and demonstrated to be an effective 
therapy, with precise dose distribution, reduced total 
treatment time and cost as well as increased patient com-
fort [4,5]. 
According to evidences accumulated in recent years, 
prostate cancer appears to be particularly sensitive to 
fractionation, much more than the healthy tissues also af-
fected by radiotherapy. This sensitivity appears in a low 
value of the α/β parameter of the linear-quadratic (LQ) 
model, where to calculate the equivalence between differ-
ent fractionation schemes used in clinical practice, a val-
ue of α/β between 1.5 and 3.0 Gy is usually considered 
[6]. All of this has led to the proliferation of clinical stud-
ies and applications of hypofractionation in HDR-BT for 
prostate cancer, as in case of EBRT [7,8]. 
Recently, the possibility of single fraction monother-
apy HDR-BT comparable to treatments involving several 
fractions has been explored. Mavroidis et al. [9] estimated 
the dose of that single fraction and found that a dose be-
tween 19.2 and 19.7 Gy is required to produce a tumor con-
trol equal to or greater than that of a scheme with 4 frac-
tions, 9.5 Gy each, specifically 95.9% to 97.8% vs. 93.5% to 
97.8%. However, for the latter scheme, a biochemical con-
trol probability (BC) at 5 years between 91% and 97% was 
obtained for low- and intermediate-risk patients [10,11,12], 
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while for the same groups of patients, 66 ±6% and 82 ±3%, 
both at 95% confidence interval (CI) for single doses of 
19.0 Gy [13] and 20.5 Gy [14], respectively, were found. 
These differences between predictions and clinical 
results could be due to the fact that the LQ model is not 
appropriate for high doses per fraction, requiring some 
modification in order to be employed in this context 
[15,16], or the value of the α/β parameter obtained in the 
region of low doses per fraction is not valid when these 
doses per fraction are high [17]. 
In this work, we analyzed the discrepancies between 
the published clinical results and the predictions of the 
radiobiological models to determine the value of ab-
sorbed dose required in an extreme, single fraction, hy-
pofractionation regime in HDR-BT monotherapy, leading 
to a biochemical failure rate similar to that of the most 
widely used regimes. In order to do that, we analyzed 
the published HDR-BT clinical results, establishing 
a dose-response relation in terms of BC by means of sta-
tistical methods based on a Monte Carlo procedure. 
Material and methods 
Clinical data analyzed 
The clinical data analyzed in the present work were 
collected after a systematic search in PubMed in January 
2019, with key terms including “high-dose-rate brachy- 
therapy” or “HDR brachytherapy”, “prostate cancer”, 
and “monotherapy”, followed by a more detailed search 
within the bibliography found in the first step, and by 
looking for prospective or retrospective clinical studies 
verifying the following conditions: 
1. HDR 192Ir interstitial BT was the only radiotherapy 
technique used, without EBRT. 
2. The endpoint considered was BC obtained as 1 minus 
prostate-specific antigen (PSA) failure, defined as na-
dir plus 2 ng/ml, according to [18]. 
3. The BC at 5 years for the fractionation schemes con-
sidered was explicitly provided. Studies in which this 
endpoint may be obtained indirectly from their out-
comes were not considered. 
4. Patients of low- and/or intermediate-risk were in-
cluded. BC values in both groups together or sepa-
rately were considered. Studies involving high-risk 
patients were considered only if BC was applied for 
low- or intermediate-risk patients, separately. 
Table 1 summarizes characteristics of the 13 clinical 
studies [10,11,12,13,14,19,20,21,22,23,24,25,26] verifying 
the conditions mentioned above. They include 16 differ-
ent fractionation schedules, with a number of fractions 
varying between 1 and 9, for a total of 22 empirical data 
sets. Table 1 includes dosimetric details of these fractions, 
the risk group, and the BC at 5 years, with the 95% CI 
when quoted by the study authors. 
Dose response model 
In this study, BC was described by means of [27]: 








dD = D D50
dBC
dD  
is the maximum normalized dose-response gradient, and 
D50 is the total dose needed to achieve BC = 50%. 
To compare different HDR-BT schemes, we consid-
ered the biologically effective dose [28]: 
 (2)BED(D, d) = D  1+ .
d
α/β
Here D is the total dose, d is the dose per fraction, and 
the α/β LQ parameter allows quantifying the sensitivi-
ty of fractionation. The equivalent dose EQD2 is defined 
as the total dose imparted in a scheme with 2 Gy per 
fraction that produces the same biological effect than 
another scheme: 
BED(EQD2, 2 Gy) = BED(D, d). (3)
Using equation (2) we have: 
 (4)EQD2 = D .
d + α/β 
2 Gy + α/β
The total treatment time of the various schemes ana-
lyzed was not considered and its effect is not included in 
equations (2) and (4). 
It is possible to establish a dose-response relationship 
including all the fractionation schemes, in which the total 
dose D in equation (1) is substituted by the equivalent 





BC =   1 + =   1 +  .
d + α/β
2 Gy + α/β4g 4g–1
–1
Statistical methods 
The BC data shown in Table 1 were used to determine 
the free parameters D50, g, and α/β in equation (5), using 
the Monte Carlo procedure described below. 
1.  For each clinical study in Table 1, two parameters were 
calculated. The first one, μ, was chosen as the average 
BC provided in the study (column #7 in the Table 1). 
In three studies of [12], where 95% CI (column #8) is 
markedly asymmetric with respect to the average val-
ue, μ was chosen as the center of the CI. 
The second parameter, σ, was calculated as: 
1
3.92σ =          (BChigh – BClow)  (6)
for the studies providing 95% CI [(BC)high, (BC)low], and its 
variation with the number of patients, n, was fitted with 
the function 
1
2σ = a n – , with a being the fitting parameter. 
The data obtained are shown in Figure 1 with symbols 
and the curve fitted to all these data is the dashed one. If 
the data shown by open squares, considered as outliers, 
are not included in the fit, the solid curve is obtained. As 
both fitting curves produce the same final results, the σ 
values considered in our analysis were calculated with 
equation (6) or obtained with the dashed fitting curve de-
pending on availability of 95% CI. 
The value 3.92 = 2 × 1.96 in equation (6) is due to the 
fact that CI corresponds to 95% probability. The μ and σ 
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values used in our analysis are those shown in the last 
two columns in Table 1. 
2.  Values of BC were sampled for each clinical study an-
alyzed according to the corresponding Gaussian dis-
tributions N[μ, σ], and the function in equation (5) was 
fitted to the set of values obtained (or subsets character-
ized by specific fractionation schemes) using the Leven-
berg-Marquardt method [29]. As a result, the values of 
D50, g, and α/β were found. In this process, the distri-
butions were truncated to avoid BC values above 100. 
It must be indicated that, in case of asymmetric CI, it 
is possible to consider other distributions for BC. Howev-
er, as it has been shown in [30], they produce equivalent 
results. 
3.  Step 2 was repeated 10,000 times, thus providing the 
statistics required to determine the distributions of D50, 
g, and α/β. For each of them, the median and the 95% 
CI were calculated. The uncertainties quoted in this 
work correspond to these CIs, which are indicated be-
tween square parentheses accompanying the average 
values of the corresponding quantity. 
To check the convergence of procedure, fits in which 
α/β was fixed to a given value were performed. In these 
fits, D50 and g were obtained as well as their c2 per degree 
of freedom, c2/v. 
Results 
We used equation (4) to calculate EQD2 correspond-
ing to the fractionation schemes analyzed, with α/β 
= 1.5 and 3.0 Gy as the values usually employed in the 
last years for comparing different fractionation schemes 
Table 1. Summary of the prostate cancer HDR-BT monotherapy data analyzed. The number of sessions, the dose 
per fraction, d, the total dose, D, the number of patients, the average BC at 5 years endpoint, and its 95% CI are 
given for low (L)- and intermediate (I)-risk patients. The last two columns show the μ and σ considered in the 
fitting procedure described in the text. For the study of [21], the total dose and dose per fraction averages were 
considered. The study [22] was included despite involving three high-risk patients. The BC of [23] is for 6 years 
Reference Fractionation schedule Risk # of  
patients 
BC at 5 years (%) μ σ 
n d (Gy) D (Gy) Average 95% CI 
[10] 
4 9.5 38.0 
L/I 
171 91.0 91.0 2.6
6 7.0 42.0 77 87.0 87.0 3.8 
[11] 4 9.5 38.0 
L 196 94.0 94.0 2.4 
I 81 92.0 92.0 3.7 
[12] 
4 9.5 38.0 
L/I 
319 97.0 [93.5, 98.7] 96.1 1.3 
2 12.0 24.0 79 87.0 [68.0, 95.1] 81.6 6.9 
2 13.5 27.0 96 90.0 [63.8, 97.6] 80.7 8.6 
[13] 1 19.0 19.0 L/I 60 66.0 [60.0, 72.0] 66.0 3.1 
[14] 1 20.5 20.5 L/I 60 82.0 [79.0, 85.0] 82.0 1.5 
[19] 9 6.0 54.0 
L 15 85.0 [66.0, 100.0] 85.0 8.7 
I 29 93.0 [83.0, 100.0] 93.0 4.3 





85.1 [72.5, 94.5] 85.1 5.6 
10.5 31.5 19 
11.0 33.0 19 
11.5 34.5 22 
[22] 3 15.0 45.0 L/I 77 96.7 96.7 3.8 
[23] 6 7.25 43.5 L/I 448 98.6 [96.9, 99.4] 98.6 0.6 
[24] 3 11.5 34.5 
L 198 96.1 [92.4, 99.3] 96.1 1.8 
I 135 96.1 [92.1, 99.9] 96.1 2.0 
[25] 2 13.5 27.0 L/I 119 96.0 96.0 3.1 
[26] 
7 6.5 45.5 I 48 97.4 97.4 4.9 
7 7.0 49.0 
L 26 100.0 100.0 6.6 
I 52 88.9 88.9 4.7 
9 6.0 54.0 I 39 100.0 100.0 5.4 
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in prostate cancer. BC at 5 years of the various clinical 
studies are shown in Figure 2, as a function of EQD2 and 
grouped according to their fraction number. 
No correlation among the various fractionation 
schemes was observed, particularly for the two single 
fraction schemes included (red open squares). This may 
be due to the fact that the α/β considered could be incor-
rect. To investigate whether this is the case, we analyzed 
the data by using the Monte Carlo procedure described 
above. The results obtained for the medians and 95% CI 
of distributions of the fitting parameters are shown in 
Figure 3, with dose d90% additionally given. This is the 
dose required to produce, in a single fraction scheme, 
BC = 90% at 5 years, which is approximately the average 
BC value found for all the studies analyzed. 
Three datasets were studied. The first one included all 
the schemes shown in Table 1. The other two correspond-
ed to more restricted regions of dose per fraction, and were 
considered to study whether the fitting parameters change 
significantly. We analyzed d ≥ 9.5 Gy, choosing large doses 
per fraction, where the failure of LQ model has been sug-
gested (e.g. [16]), and d ≤ 11.5 Gy, neglecting the highest 
doses per fraction and, in particular, the only two studies 
with a single dose. The curves obtained with fitting parame-
ters determined in the Monte Carlo analysis are shown with 
solid lines in Figure 3, together with c2/v values of the fits. 
Figure 4 shows the results obtained by fitting the 
function in equation (5) to all data included in Table 1 
for fixed values of α/β. The variation of D50, g, c2/v, and 
d90% with α/β is shown in the several panels. The verti-
cal dotted lines indicate the value α/β = 22.8 Gy, where 
c2/v = 1.90 reaches a minimum that corresponds to 
D50 = 27.7 Gy, g = 1.45, and d90% = 22.3 Gy. In Figure 2C, 
we show BC at 5 years of the various clinical studies an-
alyzed as a function of EQD2, grouped according to their 
fraction number for this value of the α/β parameter. 
Fig. 1. σ, defined in equation (6) vs. the number of patients 
n of clinical studies with CI available. The curves are fits of 
the function 
1
2σ = a n –  to all data (dashed curve) and to data 
shown with solid circles (solid curve), excluding the outliers 
(open squares). The values of the fitting parameter a in both 
cases are given
Fig. 2. BC at 5 years vs. EQD2 calculated using equation (4) 
with α/β = 1.5 Gy (a), 3.0 Gy (b), and 22.8 Gy (c). Data are 
grouped according to the number of fractions 
These results are consistent with those obtained in 
the Monte Carlo analysis where, for the three datasets 
considered, a high value of α/β and above 18 Gy was 
found. The situation observed for c2/v in Figure 4C is 
very indicative: after a rapid reduction and once the min-
imum is reached, c2/v remains almost constant with in-
creasing α/β. 
Discussion 
The analysis of clinical studies about monotherapy 
HDR-BT in prostate cancer indicate that high α/β values 
are required to describe adequately the data available. As 
shown in Figure 3C, this occurs even if only the data with 
doses per fraction 6 Gy < d ≤ 11.5 Gy are considered and 
the schemes with a single fraction are excluded. 
When all data are included, the single fraction sched-
ule producing BC = 90% is d90% = 22.3 Gy [21.5, 24.2 Gy], 
which corresponds to EQD2 = 40.6 Gy [32.1, 46.6 Gy]. In 
this case, a single fraction of 19 Gy used in a study by Pra-
da et al. [13] and corresponding to EQD2 = 32.0 Gy would 
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produce BC = 69.6% [64.8, 74.6%], close to the value of BC 
= 66% [60, 72%] quoted by these authors, and much small-
er than the prediction of Mavroidis et al. who estimated 
BC above 95% for a single fraction between 19.2 and 
19.7 Gy [9]. On the other hand, we found BC = 81.4% [78.6, 
84.0%] for a single fraction of 20.5 Gy, for which Prada 
et al. obtained 82% [79.0, 85.0%] [14]. 
Fig. 3. BC data vs. EQD2 grouped according to the number 
of fractions. The results in the inset tables are the medians 
and 95% CI of the fitting parameter distributions obtained 
in the Monte Carlo procedure. Solid curves represent the 
function in equation (5) obtained for the medians of the 
Monte Carlo fitting parameters. The c2/v for these fitting 
curves are given. A) All the data in Table 1 were includ-
ed in the Monte Carlo analysis. B, C) Only the data with  
d ≥ 9.5 Gy and d ≤ 11.5 Gy, respectively, were included. 
Finally, the d90% values are also shown 
Fig. 4. Dependence of (A) D50, (B) g, (C) c2/v, and (D) d90% 
with α/β. For each value of α/β, a fit of the function in 
equation (5) to all the data considered in the present anal-
ysis was performed. Vertical dotted lines correspond to 
α/β = 22.8 Gy, where c2/v reaches a minimum 
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The lower α/β average obtained in the three data sub-
sets analyzed was 21.3 Gy [12.8, 64.3 Gy] (see Figure 3B), 
well above 1.5 and 3.0 Gy values usually considered (Fig-
ure 2). Our results indicate low sensitivity of prostate can-
cer to fractionation with high doses per fraction, much 
lower than that indicated by the small α/β mentioned 
above. This has been claimed by other authors, high- 
lighting that the design of hypofractionated schemes for 
prostate cancer radiotherapy need to be proceed with 
caution [8]. 
It is worth noting that LQ model results are fully cor-
rect only in the dose per fraction region where its defining 
parameters were fitted. Low values of α/β are consistent-
ly obtained in studies where low doses per fraction are 
used [31]. However, some authors have observed that 
the LQ model using these low values of α/β for high 
doses per fraction, produces local control levels below 
expectations [32], which is in agreement with our find-
ings. Therefore, we can consider the LQ model as a valid 
approximation in a restricted range of dose per fraction, 
whereas a pragmatic solution recently proposed for cer-
vix cancer [17] can be adopted using an α/β value when 
one compares fractionations in which low doses per frac-
tion are given, and a different one to evaluate schedules 
in the high-dose per fraction region. 
This high α/β explains why the single fraction 
schemes have not produced the clinical results expected 
from the LQ model, when the α/β determined for low 
doses per fraction is considered [13,14]. In this case, rela-
tively high EQD2, calculated with low values of α/β, pro-
duce modest BC probabilities (see Figure 2). 
In this respect, it is worth mentioning that three stud-
ies were not included in our analysis because they do not 
match the selection criteria. The first one is that of Hoskin et 
al. [33], who quoted BC = 94% for treatments with a single 
fraction of 19 or 20 Gy for 49 months of follow-up for 49 
patients having intermediate- or high-risk disease. These 
BC values are similar to those shown by other fractionation 
schemes, with high control rates confirmed after comple-
tion of patient’s follow-up (as the authors themselves indi-
cate). Moreover, a larger patient sample would be desirable. 
In the second study, Mendez et al. [34] indicated that 
the biochemical failure rate found at 30 months was 
around 10%, which is larger than expected for a single 
fraction of 19 Gy. 
Finally, Barnes et al. [35] included 28 patients with 
low- and intermediate-risk, and observed 80.6% biochem-
ical failure-free survival after 3 years. This value was qual-
ified by the authors as a suboptimal biochemical control. 
The estimated D50 is significantly smaller than those 
of classical schemes. For the whole sample of studies, we 
Table 2. Dose per fraction needed to reach BC values of 90 and 95% according to the results of the present 
work. Results for various schemes including 1 to 4 fractions are presented 
d (Gy) 
BC 1 fraction 2 fractions 3 fractions 4 fractions 
90% 22.3 [21.5, 24.2] 13.8 [13.4, 14.0] 10.2 [9.6, 10.5] 8.1 [7.4, 8.5] 
95% 24.3 [23.0, 27.9] 15.1 [14.6, 16.2] 11.2 [10.9, 11.6] 9.0 [8.6, 9.3]
found D50 = 27.8 Gy, while Trada et al. obtained 39.8 and 
45.1 Gy, respectively, for low- and intermediate-risk pa-
tients, after analyzing various clinical studies of prostate 
cancer EBRT, with fractions between 1.8 and 2.0 Gy [36]. 
This may be due (at least to some extent) to the shorten-
ing in the overall treatment time in HDR-BT schemes with 
respect to EBRT, which could produce an increase of the 
treatment effect for low- and intermediate-risk patients [37]. 
With regards to g, the value obtained for the whole set 
of clinical studies analyzed was g = 1.45 [0.98, 1.89]. Trada 
et al., in the same revision above mentioned, quoted 
average g values between 1.2 and 3.2 [36]. In a similar 
work, in which studies using hypofractionation were ex-
cluded, Diez et al. [38] found g = 1.78 [0.54, 3.02] for low-
risk patients and g = 1.63 [1.13, 2.14] for intermediate- and 
high-risk patients. Even though these values are compati-
ble with ours, it is worth noting that the non-randomized 
studies analyzed by Diez et al. defined biochemical failure 
according to ASTRO criterium instead of that used in our 
study. 
Our results show that doses used in a single fraction 
must be above 22 Gy to obtain BC ≥ 90% and above 24 Gy 
for BC ≥ 95%. A single fraction of 22-24 Gy may compro-
mise the toxicity for normal tissues, and it would be inter-
esting to analyze this aspect with a methodology similar 
to that used in our study, including possible changes in 
the α/β of normal tissues for high doses per fraction. In 
any case, it is interesting to consider other fractionation 
alternatives. The results are shown in Table 2. For 3 and 
4 fraction schemes, doses per fraction similar to those al-
ready utilized in some of the studies shown in Table 1 
were found. The only exception was that of Kukiełka 
et al., who used 3 fractions of 15 Gy [22]; however, ac-
cording to our calculations, it is not necessary to reach 
such high values to achieve adequate BC. For 2 fraction 
schemes and BC = 90%, we found that fraction doses of 
approx. 13.5 Gy are necessary, a value similar to that con-
sidered in references [12,25]. 
A fractionated treatment can be analyzed in terms of 
BED. For a single fraction of 22.3 Gy and assuming α/β 
= 22.8 Gy, we found BED = 44.1 Gy for BC = 90% (see 
eq. (2)), much smaller than those obtained, assuming the 
low α/β values currently adopted (188.1 Gy and 353.8 Gy 
for α/β equal to 3 Gy and 1.5 Gy, respectively). α/β and 
BED can be considered as mutually dependent quantities 
that must be chosen according to the specific treatment 
and fractionation. Reference BED values must be used 
carefully considering the clinical context, for which they 
were estimated. For example, Zaorsky et al. [39] used 
the same α/β for EBRT, with doses per fraction relative-
ly low, and HDR-BT. These authors concluded that in-
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creasing the BED obtained for α/β = 1.5 Gy above 200 Gy 
does not produce any effect. However, the BED may be 
wrongly calculated for HDR-BT because of the very low 
α/β value considered. In the same way, as can be seen 
in Figure 2, the value of EQD2 depends on the value of 
α/β considered to calculate it. Therefore, the EQD2 values 
estimated for the set of treatments studied in this work 
are valid only in the specific range of doses per fraction 
analyzed. 
The results presented in this work have some limita-
tions: 1. The dataset fulfilling the criteria imposed is small 
and is affected by uncertainties that are considerably 
large; 2. There is some heterogeneity among treatment 
techniques employed in the different studies; 3. The two 
single fraction studies included in our analysis belong 
to the same institution. In addition, the use of hormonal 
therapy, the implant technique, the heterogeneity of ab-
sorbed dose, different criteria for prescribed dose used 
by various institutions, limitations imposed on dose that 
normal tissues may receive, uncertainties due to the pres-
ence of low and intermediate patients in the cohort ana-
lyzed, etc., are the conditions that may modify the value 
of the fitted parameters. 
Conclusions 
The α/β value of 22.8 Gy found in our analysis, with 
a range of dose per fraction between 6.0 and 20.5 Gy, is 
much greater than 1.5 Gy or 3.0 Gy currently considered 
for prostate cancer radiotherapy with low doses per frac-
tion. This high value of α/β explains reasonably well the 
data available in the region of the high doses per fraction 
considered. The absorbed dose in monotherapy HDR-BT, 
in a single fraction scheme, allowing to obtain BC = 90% 
and 95% are 22 Gy and 24 Gy, respectively. 
The limitations of our analysis, such as the strong in-
fluence of single fraction schemes in the fitting procedure 
or the heterogeneity of data, can be overcame by consid-
ering additional clinical studies. 
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